I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope address Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Docket No.: 30610/40679A (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Patent Application of: Steven Jungles et al.

Application No.: 10/563,418

Filed: January 4, 2006

Stable Tablet Formulation

Confirmation No.: Not yet Assigned

Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO-1449. It is respectfully requested that the references be made of record and appear among the "References Cited" on any patent to issue from this application.

Copies of documents B1-B9 and C1-C16 are submitted with this paper.

This Information Disclosure Statement is being submitted before the mailing of a first Office Action (37 C.F.R. §1.97(b)(3)). Therefore, no fee is believed to be due. However, the Director is hereby authorized to charge any deficiency in the fees filed, asserted Application No.: 10/563,418 Docket No.: 30610/40679A

to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 30610/40679A. A duplicate copy of this paper is enclosed.

Dated: June 13, 2006

Respectfully submitted,

Shelley C. Danek, Ph.D. Registration No.: 57,712

Registration No.: 51,712 MARSHALL, GERSTEIN & BORUN LLP 233 S. Wacker Drive, Suite 6300 Sears Tower

Chicago, Illinois 60606-6357 (312) 474-6300 Agent for Applicants

PTC/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE did to respond to a collection of information unless it contains a valid CMB control number. Complete if Known Substitute for form.1449A/B/PTO Application Number 10/563,418 INFORMATION DISCLOSURE STATEMENT BY APPLICANT January 4, 2006 Filing Date Steven Jungles et al. First Named Inventor Not Yet Assigned Art Unit (Use as many sheets as necessary) Not Yet Assigned Examiner Name 30610/40679A Attorney Docket Number of 2

	A1 A2 A3	Document Number Number-Kind Code ² (if known) 2,541,717	Publication Date MM-DD-YYYY	ISHED APPLICATION DOCUMENTS Name of Patentee or	Relevant Passages or Relevan
	A1 A2 A3			Applicant of Cited Document	Figures Appear
	A2 A3	2 541 717			
	A3_			Petering et al. Waller et al.	
		2,601,215			
		2,603,643	07-15-1952	Kirchsteiner et al.	
	A4	2,955,110		Patterson et al.	
	A5	3,505,329		Weinstock et al.	
	A6	4,371,514	02-01-1983	Nagatsu et al.	
	A7	4,540,783	09-10-1985		
	A8	4,550,109	10-29-1985		
	A9	4,587,340	05-06-1986		
	A10	4,595,752	06-17-1986	Azuma et al.	
	A11	4,649,197	03-10-1987	Uchino et al.	
	A12	4,665,182	06-12-1987	Nichol et al.	
	A13	4.701,455	10-20-1987	Nichol et al.	+
	A14	4,713,454	12-15-1987	Sakai et al.	
	A15	4,752,573	06-21-1988		
	A16	4,758,571	07-19-1988		
	A17	4.774.244	09-27-1988	Curtius et al.	
	A18	4.920.122	04-24-1990	Naruse et al.	
	A19	4,937,342	06-26-1990	Kurono et al.	
	A20	5,037,981	08-06-1991	Kurono et al.	
	A21	5,198,547	03-30-1993	Bailey et al.	
-	A22	5,350,851	09-27-1994	Bailey et al.	
	A23	5,401,844	03-25-1995	Ayling et al.	
	A24	5,698,408	12-15-1997	Rokos	
	A25	5.753.656	05-19-1998	Sakai et al.	
	A26		02-23-1999	Gross	
	A27		05-11-1999	Pfleiderer et al.	
	A28		07-13-1999	Werner	
	A29		08-31-1999	Cooke et al.	
-	A29		01-04-2000	Muller et al.	
	A30		12-19-2000		
	A31		08-14-200	1 Gross	
-	A32		08-27-200		
	A34		06-25-200	2 Kashiwagi et al.	
			04-08-200	3 Rabelink et al.	
	A35		06-20-200		
	A36		08-08-200		
	A37	2002/0100045	12-12-200		
	A38		02-13-200		

	Date
Examiner	Considered
Examiner Signature	

PTO/SBI08alb (08-03)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ted to respond to a collection of information unless it contains a valid CMB control number.

Under the Paperwork Reduction Act of 1995, no persons are req Complete if Known Substitute for form 1449A/B/PTO Application Number 10/563.418 January 4, 2006 INFORMATION DISCLOSURE Filing Date Steven Jungles et al STATEMENT BY APPLICANT First Named Inventor Not Yet Assigned Art Unit (Use as many sheets as necessary) Not Yet Assigned 30610/40679A Attorney Docket Number of 2 Sheet

		FOREIG	ON PATENT DO	OCUMENTS		_
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	70
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				Ŀ
	B1	CA 2420374	02-24-2003			⊢
	B2	EPO 079 574	05-25-1983			⊢
	B3	EPO 191 335	08-20-1986			+-
	B4		03-16-1992			-
	B5	JP 59-021685 (Abstract only)	02-03-1984			⊢
	B6	JP 9-157270 (Abstract only)	06-17-1997			-
	B7	WO 2005 049000	06-02-2005			+-
	B8	WO 2005 049614	06-02-2005			+-
	B9	WO 2005 065018	07-21-2005			

EXAMINER, Initial if reference considered, whether or not clustion is in conformance with MPEP 600. Draw to a through cluster In the in conformance with MPEP 600. Draw to a through cluster In the incommendation of considered, include copy of this form with need commendation to applicant. Applicants under use sets of the conformation of the MRM Codes of Conformation and Codes of Commendation and Codes of C

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (b magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, c	
	C1	Bernaggar and Blau, Mol. Genet. Metabol., 77:304-313 (2002)	1-
	C2	Blau et al., Disorders of tetrahydrobiopterin and related biogenic amines. In: Schver CR, Beaudet AL, Sly WS, Valle D, Childs B, Vogelstein B, eds. The Metabolic and Molecular Rases of Inherited Disease: 8th ed. New York: McGraw-Hill, pages 1725-1776 (2001)	L
	C3	Christensen et al. Gene Therapy, 7:1971-1978 (2000)	+
	C4	Christensen et al., Mol. Gent. and Metabol., 76:313-318 (2002)	+-
	C5	Davis et al., Eur. J. Biochem., 173:345-351 (1988)	+-
	C6	Davis et al., Eur. December for Drug Evaluation and Research (CDER) Draft Guidance for Industry ANDAs: Pharmaceutical Solid Polymorphism Chemistry, Manufacturing, and Controls Information, December 2004.	
	C7	Hapley, N. Engl. J. Med., 348(17):1723 (2003)	-
	C8	Matsuura et al., J. Biochem., 98:1341-1348 (1985)	+-
	C9	Matsuura et al., Chem. Lett., 735-738 (1984)	+-
	C10	Mateuira et al. Heterocycles, 23(12):3115-3120 (1985)	-
	C11	Liu et al., Arts, Cells, Blood, Subs and Immob, Biotech, 30(4):243-257 (2002)	+
	C12	Schircks et al. Hely Chim. Acta. 60:211 (1977)	+-
	C13	Sugimoto and Matsuura, Bull. Chem. Soc. Japan, 48(12):3767-3768 (1975)	-
l	C14	Sugimoto et al., Bull, Chem. Soc. Japan, 52(1):181-183 (1979)	+-
	C15	Visontini et al., Helv. Chim. Acta., 52:1225 (1969)	+-
	C16	Whiteley et al., Anal. Biochem., 137(2):394-6 (1984)	

"EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

Examiner		Date	12/14/2010
Signature	/James Rogers/	Considered	12/17/2010